Sarepta Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sarepta Therapeutics's estimated annual revenue is currently $645.6M per year.
- Sarepta Therapeutics received $375.0M in venture funding in November 2017.
- Sarepta Therapeutics's estimated revenue per employee is $594,986
- Sarepta Therapeutics's total funding is $1.4B.
- Sarepta Therapeutics's current valuation is $6.2B. (January 2022}
- Sarepta Therapeutics has 1085 Employees.
- Sarepta Therapeutics grew their employee count by -3% last year.
Sarepta Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Sarepta Therapeutics?
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company's programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. For more information, please visit www.sarepta.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Sarepta Therapeutics News
More than three dozen medical experts are urging the Food and Drug Administration to approve a Sarepta Therapeutics medicine for combating Duchenne muscular dystrophy, a rare disease that causes muscles in boys to stop working and eventually results in death because they can no longer breathe. ...
Sarepta is working hard to develop precision genetic medicines for patients with rare diseases who often have limited or no treatment options, including Duchenne. Clinical trials are critical for understanding the safety and effectiveness of our investigational medicines. The results of these st ...
Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior yearIn light of its continued over-performance, Sarepta raises its full-year product revenue guidance by $40 million to between $605 million to $615 million CAMBRIDGE, Mass., No ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) fell more than 39% last month, according to data provided by S&P Global Market Intelligence ...
Charles Schwab Investment Management Inc. grew its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 8.9% in the 2nd ...
32 days have passed by since the last earnings report for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and the new quarterly results look set to ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Sarepta Therapeutics Funding
|2002-03-27||$22.0M||Private Equity Fina||Article|
|2005-11-15||$22.6M||Undisclosed||Rodman and Renshaw LLC||Article|
|2009-02-04||$16.5M||Undisclosed||Eastbourne Capital Management||Article|
|2009-08-21||$30.0M||Undisclosed||Jefferies & Company Inc||Article|
|2011-04-04||$30.0M||Undisclosed||Lazard Capital Markets LLC, Piper Jaffray & Co||Article|
|2017-07-25||$287.5M||Undisclosed||Goldman Sachs & Co. LLC||Article|